| Literature DB >> 34392463 |
Felix Behling1,2, Imane Bersali3, Antonio Santacroce4, Johann Hempel5,6, Kosmas Kandilaris5,7, Jens Schittenhelm5,7, Marcos Tatagiba3,5.
Abstract
Entities:
Mesh:
Year: 2021 PMID: 34392463 PMCID: PMC8827336 DOI: 10.1007/s10143-021-01620-3
Source DB: PubMed Journal: Neurosurg Rev ISSN: 0344-5607 Impact factor: 2.800
Fig. 1MR-images throughout the disease course showing the extent of the tumor prior to the first treatment with gamma knife (A and B) and further tumor growth 2 years later (C and D). Subsequently, the tumor was partially resected and after further growth a second round of gamma knife was applied. Afterwards, the tumor showed further progression (E and F) and gross total resection was done (G and H). Two years later, another tumor recurrence occurred (I and J) prompting another gross total resection now revealing the histology of a MPNST (K and L). Besides all efforts, the tumor showed a massive progression (M) and the patient deceased shortly afterwards
Fig. 2The histopathological images show the recurrent schwannoma after the gross total resection in our center as a moderately cellular spindle cell tumor without signs of atypia (A) and retained nuclear expression of H3K27me3 (B) (magnification 100 × . A biopsy of the next recurrence 2 years later revealed again a schwannoma. A spindle cell tumor of moderate cellularity consisting of plump neoplastic cells again with retained nuclear expression of H3K27me3 was seen (C and D) (magnification 100 ×). After the second gross total resection, we observed a highly cellular tumor of moderately atypical cells with signs of intraluminal vascular herniation (E, magnification 200 ×) and several mitotic figures (F, magnification 400 ×). Now, loss of nuclear expression of H3K27me3 in the tumor cells was detected, with positive endothelial cells, which served as an internal control (G, magnification 400 ×)
Fig. 3Timeline summarizing the course of disease and treatment
List of reported vestibular schwannomas with malignant transformation in the literature with corresponding clinical data
| Author,year | Age,Sex | NF2 | 1st treatment | RTx | Marginal dose (Gy) | Latency (y) | 2nd pathology | Survival (m) |
|---|---|---|---|---|---|---|---|---|
| Comey, 1998 | 44, M | N | RTx | GK | 14.4 | 5.5 | MTT | 12 |
| Noren, 1998 | 18, F | Y | RTx | GK | 20 | 5 | MTT | n/a |
| Pollock, 1998 | n/a | n/a | RTx | GK | 16 | 7 | MTT | n/a |
| Thomsen, 2000 | 19, F | Y | RTx | GK | 12 | 6 | Sarcoma | 24 |
| Baser 2000 | n/a | Y | RTx | n/a | n/a | n/a | MPNST | n/a |
| n/a | Y | RTx | n/a | n/a | n/a | MPNST | n/a | |
| n/a | Y | RTx | n/a | n/a | n/a | MPNST | n/a | |
| Hanabusa, 2001 | 51, F | N | S | GK | 15 + 14 | 0.5 | Sarcoma | 4 |
| Bari, 2002 | 28, F | Y | RTx | GK | 15 | 4 | MPNST | 3 |
| Shin, 2002 | 26, F | N | S | GK | 17 | 6 | MPNST | 10 |
| Ho, 2002 | 14, F | Y | RTx | FRT | 18 | 0.6 | n/a | 0.5 |
| McEvoy, 2003 | 22, M | Y | RTx | GK | 15 | 2 | n/a | 3 |
| Wilkinson, 2004 | 53, M | N | S | n/a | n/a | 7 | MPNST | n/a |
| Muracciole, 2004 | 61, F | N | RTx | GK | 10 + 12 | 6 | MTT | n/a |
| Kubo, 2005 | 51, M | N | S | GK | 14 | 0.7 | MPNST | 12 |
| Hasegawa, 2005 | 56, F | N | RTx | GK | 12.7 | 5.7 | MPNST | 12 |
Maire, 2006 Markou, 2012 | 45, F | N | S | FRT | n/a | 18 | MPNST | n/a |
| Van Rompaey, 2009 | 53, F | N | S | SRS | 12 | 8 | MPNST | n/a |
| Yang, 2010 | 74, M | N | S | SRS | 12.5 | 6 | Sarcoma | 1 |
| Dematriades, 2010 | 27, M | N | S | GK | 15 | 10 | MPNST | 6 |
| Akamatsu, 2010 | 67, F | N | S | GK | 12 | 7.5 | MPNST | n/a |
| Tanbouzi, 2011 | 15, M | Y | RTx | GK | 13.5 | 5 | MPNST | 3 |
Schmitt, 2011 Milligan, 2012 | 51, M | N | RTx | GK | 12 | 7.5 | Sarcoma | 7 |
| Puataweepong, 2012 | 34, F | N | S | FRT | n/a | 6 | MPNST | n/a |
| Yanamadala, 2013 | 46, F | N | S | GK | 14 | 6 | MPNST | 12 |
| Kuzmik, 2013 | 73, F | N | RTx | SRS | 13 | 0.5 | MPNST | 2 |
| Seferis, 2014 | 46, F | N | S | GK | 12 | 5.5 | MPNST | n/a |
| Se, 2016 | 49, F | N | RTx | GK | 12.5 | 6 | Sarcoma | 6 (alive) |
| Simmermacher, 2017 | 39, F | N | RTx | FRT | n/a | 13 | MPNST | n/a |
| Frischer, 2018 | n/a | N | RTx | GK | 13 | 8 | MPNST | 9 |
| Haq, 2019 | 54, M | N | S | GK | 10 | 9 | MPNST | 9 (alive) |
| Peker, 2019 | 40, F | N | S | CK | n/a | n/a | MPNST | n/a |
| Tish, 2019 | 65, F | N | RTx | GK | 12 | 12 | MTT | 10 |
| Boucher, 2020 | 66, F | N | RTx | GK | 12.5 | 17 | Sarcoma | 7 |
| Sherry, 2020 | 28, F | N | S | SRS | n/a | 15 | Sarcoma | n/a |
| 68, M | Y | RTx | GK | n/a | 3 | MPNST | 12 | |
| Present case | 29, F | N | RTx | GK | n/a | n/a | MPNST | 4 |
M male; F female; NF2 neurofibromatosis type 2; n/a not available; S surgery; RTx radiation therapy; SRS stereotactic radiotherapy; FRT fractionated radiotherapy; GK gamma-knife radiosurgery; CK cyber-knife radiosurgery; MTT malignant triton tumor; MPNST malignant peripheral nerve sheath tumor